Conjunctival tumours are abnormal growths that develop on the conjunctiva, the thin membrane covering the white of the eye and lining the eyelids. They may arise from epithelial cells, melanocytes, lymphoid tissue, blood vessels, nerves, or other structures.
Early assessment is important because benign and malignant conjunctival lesions can appear similar. At Apollo Cancer Centres, conjunctival tumours are assessed by a multidisciplinary team that may include ocular oncologists, corneal and ophthalmic surgeons, medical oncologists, haemato-oncologists, radiation oncologists, pathologists, radiologists, genetic counsellors, and ocular reconstruction specialists.
Risk Factors for Conjunctival Tumours
Conjunctival Tumour Signs and Symptoms
How Conjunctival Tumours Are Diagnosed
Diagnosis begins with a review of symptoms, lesion duration and growth, previous photographs, ultraviolet exposure, immune status, previous cancers, and personal or family history of melanoma. The ophthalmologist examines the entire conjunctiva, including the areas beneath the eyelids, because some tumours are multifocal or extend beyond the visible lesion.
Slit-Lamp Examination
Slit-lamp examination provides a magnified view of the conjunctiva and cornea.
The specialist assesses:
Location and size
Colour and pigmentation
Thickness and surface appearance
Cysts, keratin, or ulceration
Tumour blood vessels
Corneal involvement
Mobility over underlying tissue
Extension beneath the eyelids
Features suggesting invasion
Eyelid Eversion
The upper and lower eyelids may be turned outward to examine the palpebral and forniceal conjunctiva. This helps identify hidden or multifocal disease.
Clinical Photography
High-resolution photographs document the tumour's appearance and dimensions. Serial images help determine whether an observed lesion is changing.
Anterior-Segment Optical Coherence Tomography
High-resolution anterior-segment OCT provides cross-sectional images of the conjunctival and corneal epithelium.
It may help:
Identify epithelial thickening
Define the edge of ocular surface squamous neoplasia
Distinguish some epithelial lesions from deeper tumours
Monitor response to topical treatment
OCT can support diagnosis but does not replace biopsy when histological confirmation is required.
Ultrasound Biomicroscopy
Ultrasound biomicroscopy assesses the depth of a conjunctival tumour and may identify involvement of the sclera, ciliary body, or internal eye structures.
MRI
MRI of the orbits may be performed when:
A tumour appears deeply invasive
Orbital extension is suspected
Eye movement is restricted
Conjunctival lymphoma extends beyond the visible surface
Surgical or radiation planning requires further anatomical detail
CT Scan
CT may be used to assess orbital bone, regional lymph nodes, or systemic disease. It may also be useful when MRI is unsuitable.
PET-CT
PET-CT may be considered for:
Conjunctival lymphoma
Advanced conjunctival melanoma
Suspicious lymph nodes
Possible distant metastases
A conjunctival lesion suspected to be a metastasis from another cancer
Small or superficial eye lesions may not be reliably detected on PET-CT.
Excisional Biopsy
A small, localised suspicious lesion may be removed completely for diagnosis. For suspected squamous neoplasia or melanoma, a carefully planned no-touch technique is used to minimise direct handling of the tumour. Cryotherapy may be applied to the conjunctival margins.
Incisional Biopsy
A representative portion of a large or diffuse lesion may be removed when complete excision would cause unnecessary damage or when the diagnosis will determine non-surgical treatment. Incisional biopsy is commonly appropriate for suspected conjunctival lymphoma.
Mapping Biopsies
Multiple small biopsies may be used to determine the extent of diffuse or multifocal disease, particularly primary acquired melanosis with atypia or widespread epithelial neoplasia.
Lymph-Node Biopsy
A suspicious lymph node near the ear, jaw, or neck may undergo ultrasound-guided biopsy. This can confirm regional spread and influence treatment.
Sentinel Lymph-Node Biopsy
Sentinel lymph-node biopsy may be considered for selected patients with higher-risk conjunctival melanoma. It is not routinely required for every tumour.
Laboratory
The biopsy tissue is examined by a specialist ocular pathologist.
Assessment may include:
Histopathology: Determines whether the lesion is benign, pre-invasive, or malignant and identifies its cell of origin.
Margin assessment: Establishes whether abnormal cells reach the edge of the removed tissue.
Invasion assessment: Determines whether the tumour remains within the conjunctival epithelium or has entered the stroma, sclera, cornea, eye, eyelid, or orbit.
Squamous markers: Immunohistochemistry may help confirm squamous differentiation and exclude another tumour type.
Melanocytic markers: SOX10, S100, Melan-A, HMB-45, and other markers may support a diagnosis of conjunctival melanoma.
Lymphoma typing: Immunohistochemistry and flow cytometry may identify the lymphoid cell type and distinguish reactive inflammation from lymphoma.
Molecular testing: Selected conjunctival melanomas may undergo testing for BRAF, NRAS, KIT, NF1, or other alterations that could influence treatment in advanced disease.
Proliferation assessment: Mitotic activity and Ki-67 may provide information about tumour behaviour.
HPV-related testing: May be performed in selected papillomas or squamous lesions when clinically relevant.
Systemic lymphoma tests: Blood counts, blood chemistry, bone-marrow assessment, or other tests may be performed when conjunctival lymphoma is diagnosed.
Treatment-planning tests: Kidney, liver, thyroid, and other laboratory assessments may be required before systemic therapy.
No routine blood tumour marker can diagnose a conjunctival tumour. Laboratory testing is selected according to the pathological type.
Benign conjunctival tumours are not staged. Malignant tumours are staged according to their specific pathology.
For Ocular Surface Squamous Neoplasia, staging considers:
Tumour size and location
Corneal involvement
Invasion into the sclera, eyelid, eye, or orbit
Regional lymph-node involvement
Distant metastases
For Conjunctival Melanoma, staging considers:
Site and extent across the conjunctiva
Tumour thickness
Invasion of the eyelid, sclera, eye, orbit, or surrounding structures
Regional lymph-node involvement
Distant metastases
Conjunctival lymphoma is assessed according to:
One or both eyes being involved
Extent within the ocular adnexa
Regional lymph nodes
Bone marrow or organ involvement
Lymphoma subtype
Systemic staging determines whether the disease is localised to the eye or part of more widespread lymphoma.
How Conjunctival Tumours Are Treated
No-Touch Excision
Suspected conjunctival melanoma or localised ocular surface squamous neoplasia may be removed using a no-touch technique. The surgeon avoids grasping or cutting directly through the tumour. Cryotherapy may be applied to the conjunctival margins to destroy microscopic residual cells.
Corneal And Scleral Treatment
When a lesion extends onto the cornea, the involved surface epithelium may be removed. Partial-thickness scleral removal may be required if deeper invasion is suspected.
Surgery For Conjunctival Melanoma
Treatment may involve wide local excision with margin cryotherapy. Additional topical or radiation treatment may be recommended according to the tumour's extent and margin status. Regional lymph nodes are assessed clinically and through imaging or biopsy when indicated.
Enucleation Or Orbital Exenteration
Removal of the eye or orbital contents is rarely required. It may be considered when an aggressive tumour has extensively invaded the eye or orbit and cannot be controlled using more conservative treatment.
Topical Chemotherapy
Topical treatment may be used for ocular surface squamous neoplasia as primary or additional therapy.
Medicines may include:
Mitomycin C
5-fluorouracil
Interferon alfa-2b where available
Treatment can cover the entire ocular surface, which may be useful for diffuse or multifocal disease. Side effects may include redness, irritation, tearing, corneal injury, or limbal stem-cell damage.
Topical Treatment For Melanocytic Disease
Topical mitomycin C may be considered for selected intraepithelial melanocytic disease or residual primary acquired melanosis with atypia. It is not an adequate treatment for invasive conjunctival melanoma by itself.
Lymphoma Treatment
Localised conjunctival lymphoma is often treated with low-dose or standard-dose radiation according to the lymphoma subtype and extent.
Systemic or bilateral disease may require:
Anti-CD20 antibody therapy
Immunochemotherapy
Other lymphoma-directed treatment
Observation in selected indolent cases
Antibiotic treatment only in carefully selected infection-associated cases
Management is planned with a hemato-oncology team
Treatment For Advanced Conjunctival Melanoma
Unresectable or metastatic conjunctival melanoma may be treated using systemic approaches similar to those used for mucosal or cutaneous melanoma, depending on tumour biology.
Options may include:
Immune-checkpoint inhibitors
BRAF- and MEK-directed treatment for eligible BRAF-mutated tumours
KIT-directed treatment for selected KIT-altered cancers
Other molecularly targeted therapy
Clinical trials
Conjunctival melanoma is biologically different from uveal melanoma and should not automatically follow the same systemic treatment pathway.
Plaque Brachytherapy
A radioactive plaque may be placed temporarily over a selected tumour bed to treat residual or deeply invasive disease while limiting radiation to surrounding tissues. It may be considered after excision of selected conjunctival melanomas or squamous cancers.
External Beam Radiation Therapy
External radiation may be used for:
Conjunctival lymphoma
Positive or unresectable margins
Invasive squamous cell carcinoma
Conjunctival melanoma involving deeper tissues
Regional lymph-node disease
Orbital extension
Recurrent disease
Proton Therapy
Proton therapy may be considered for selected extensive, recurrent, or deeply invasive tumours when reducing radiation exposure to surrounding ocular and orbital structures could provide an advantage.
Radiation For Metastatic Disease
Radiation may be used to control painful bone lesions, brain metastases, regional lymph nodes, or other symptom-producing disease.
The outlook depends on the tumour type. Benign lesions generally have an excellent prognosis. Ocular surface squamous neoplasia is often highly treatable but can recur, particularly when margins are involved or immune suppression continues.
Conjunctival melanoma has a greater risk of local recurrence, regional lymph-node spread, and distant metastasis. Conjunctival lymphoma is often indolent, but prognosis depends on subtype and systemic involvement.
Long-term follow-up is important because some conjunctival malignancies can recur years after treatment.
Why Choose ACC for Conjunctival Tumour Treatment